Latest Intellectual Property News

IPH Limited reported a robust FY25 with revenue rising 16.6% to $710.3 million and net profit after tax up 13.2% to $68.8 million, driven by strategic acquisitions and a pivot towards organic growth and AI integration.

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.

Genetic Technologies Limited reports a 36% increase in half-year losses amid voluntary administration, followed by a recapitalisation and sale of core assets. The company pivots towards new financial services acquisitions under fresh leadership.

Beam Communications finalizes the independent valuation of its Zoleo Inc. joint venture stake at US$13.7 million and confirms plans to return capital to shareholders.

Pharmx Technologies has reported a 13% revenue increase to $7.5 million for FY25, driven by expanded partnerships and platform innovations, despite a dip in EBITDA due to heavy investment.

Opthea Limited has terminated its sozinibercept wet AMD program following Phase 3 trial failures and settled a major funding agreement, setting the stage for a strategic reset.

Etherstack plc has delivered a record half year performance in H1 2025, driven by a landmark multi-year contract with AT&T and surging recurring revenues. The wireless communications specialist is poised for sustained growth across its core markets.

Etherstack plc has reported a remarkable turnaround in its half-year results, with revenue nearly doubling and EBITDA surging by over 1500%, signaling strong momentum in mission critical communications.

Felix Group Holdings Limited announces a strategic acquisition of Nexvia Pty Ltd to boost vendor monetisation and expand its SaaS platform capabilities, supported by a $16 million capital raise. The deal is expected to increase Felix’s pro-forma ARR by 38%, positioning the company for accelerated growth.

Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.

Rhythm Biosciences has launched a $3.75 million placement alongside an offer of over 52 million new options, all contingent on shareholder approval. The move aims to bolster working capital as the company advances its cancer diagnostic products.

AdNeo Limited has issued a prospectus to facilitate secondary trading of shares issued without prior disclosure, following its acquisition of Learnt Global and a $5.65 million capital raise. The company also offers multiple options to investors, directors, brokers, and consultants as part of its growth strategy.